Recent work has shown that Withaferin A targets vimentin in soft tissue sarcomas resulting in vimentin cleavage and apoptosis [52], increasing the promise for vimentin as a target in cancers of mesenchymal origin. This evidence concerns the gene VIM and soft tissue sarcoma.